A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kato, Yukinari ^a   Kaneko, Mika Kato ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PDPN PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CHEMISTRY; CHO CELL LINE; CRICETULUS; GLYCOSYLATION; HAMSTER; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; PROTEIN PROCESSING; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; GLYCOSYLATION; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84905455049     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05924     Document Type: Article

References (35)

1. Kato Y. et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 278 51599-51605 (2003 (Pubitemid 38020404)
2. Breiteneder-Geleff S. et al. Podoplanin novel 43-kd membrane protein of glomerular epithelial cells is down-regulated in puromycin nephrosis. Am. J. Pathol. 151 1141-1152 (1997 (Pubitemid 27424324)
3. Herzog B. H. et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 502 105-109 (2013
4. Acton S. E. et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 37 276-289 (2012
5. Peters A. et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35 986-996 (2011
6. Kato Y. et al.Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 99 54-61 (2008 (Pubitemid 350239031)
7. Suzuki-Inoue K. et al. Involvement of the snake toxin receptor CLEC-2 in podoplanin-mediated platelet activation by cancer cells. J. Biol. Chem. 282 25993-26001 (2007 (Pubitemid 47443800)
8. Bertozzi C. C. et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 116 661-670 (2010
9. Kato Y. et al. Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 23 8552-8556 (2004 (Pubitemid 39540806)
10. Martin-Villar E. et al. Characterization of human PA2.26 antigen (T1alpha-2 podoplanin) a small membrane mucin induced in oral squamous cell carcinomas. Int. J. Cancer 113 899-910 (2005 (Pubitemid 40096869)
11. Kato Y. et al. Enhanced expression of Aggrus (T1alpha/podoplanin) a plateletaggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol. 26 195-200 (2005 (Pubitemid 41379745)
12. Yuan P. et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 107 563-569 (2006 (Pubitemid 44107217)
13. Kato Y. et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation- stimulating domain. Biochem. Biophys. Res. Commun. 349 1301-1307 (2006 (Pubitemid 44416399)
14. Mishima K. et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. (Berl) 111 563-568 (2006 (Pubitemid 43778961)
15. Mishima K. et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. (Berl) 111 483-488 (2006
16. Abe S. et al. A novel targeting therapy of malignant mesothelioma using antipodoplanin antibody. J. Immunol. 190 6239-6249 (2013
17. Takagi S. et al. Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. Int. J. Cancer 134 2605-2614 (2014
18. Atsumi N. et al. Podoplanin a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem. Biophys. Res. Commun. 373 36-41 (2008
19. Hirabayashi J. Yamada M. Kuno A.& Tateno H. Lectin microarrays: concept principle and applications. Chem. Soc. Rev. 42 4443-4458 (2013
20. Imamura K. Takeuchi H. Yabe R. Tateno H.& Hirabayashi J. Engineering of the glycan-binding specificity of Agrocybe cylindracea galectin towards alpha(2,3)-linked sialic acid by saturation mutagenesis. J. Biochem. 150 545-552 (2011
21. Kaneko M. K. et al. Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett. 581 331-336 (2007 (Pubitemid 46096478)
22. Ogasawara S. Kaneko M. K. Price J. E.& Kato Y. Characterization of antipodoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 27 259-267 (2008
23. Takagi S. et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 8 e73609 (2013
24. Kaneko M. et al. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/podoplanin) molecules expressed in Chinese Hamster Ovary cells. J. Biol. Chem. 279 38838-38843 (2004 (Pubitemid 39296043)
25. Suzuki H. et al. Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma. FEBS Lett. 582 341-345 (2008
26. Kaneko M. K. et al. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 103 1913-1919 (2012
27. Kato Y. et al. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl. Med. Biol. 37 785-794 (2010
28. Nakazawa Y. et al. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci 102 2051-2057 (2011
29. Marks A. et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br. J. Cancer 80 569-578 (1999 (Pubitemid 29213215)
30. Kono T. et al. Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int. J. Oncol. 31 501-508 (2007
31. Hayatsu N. Ogasawara S. Kaneko M. K. Kato Y.& Narimatsu H. Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells. Biochem. Biophys. Res. Commun. 368 217-222 (2008
32. Kato Y. et al. Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors. Biochem. Biophys. Res. Commun. 369 1041-1046 (2008
33. Chandramohan V. et al. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer 132 2339-2348 (2013
34. Kaneko M. K. et al. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem. Biophys. Res. Commun. 406 608-613 (2011
35. Ogawa M. et al. High sensitivity detection of cancer in vivo using a dualcontrolled activation fluorescent imaging probe based on H-dimer formation and pH activation. Mol. Biosyst. 6 888-893 (2010).